Read Time: 14 mins

Neurological Manifestations of SARS-CoV-2 Infection and the Role of Complement Activation

Copy Link
Published Online: Nov 9th 2022 touchREVIEWS in Neurology. 2022;18(2):86-92 DOI:
Authors: Mustafa Jaffry, Iqra Faiz, Kazim Jaffry, Nizar Souayah
Quick Links:
Article Information

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, while considered a respiratory illness, is associated with a wide range of neurological manifestations, with severity ranging from transient deficit to permanent disability and death. These neurological manifestations can be divided into central nervous system complications, which include cerebrovascular disease and encephalopathies, and peripheral nervous system complications, which involve the muscle (i.e. muscle injuries, myositis, and peripheral and cranial neuropathies). Complement overactivation has been observed clinically in many studies and is hypothesized to be involved in a variety of pathogenic mechanisms of SARS-CoV-2 infection. These include endothelial damage, thrombosis and hyperinflammation, all of which are completely interconnected and integrated. This article broadly describes the diverse neurological effects of coronavirus disease 2019 and delves into the current literature available on complement in this context.


Central nervous system, complement, coronavirus disease 2019, neurological manifestations, SARS-CoV-2, therapeutics


The coronavirus disease 2019 (COVID-19) pandemic has led to unprecedented illness and death among the global population. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can range from mild upper respiratory symptoms that subside with no lasting effects to multiorgan system failure and death.1 It can also result in numerous neurological symptoms that are less well understood.2 The complete mechanism of these manifestations has yet to be elucidated, although significant progress has been made.3 The complement system is part of natural human immunity and consists of a series of more than 20 proteins, which progress through proteolytic pathways for host defence and regulation.4 This system has been implicated in the pathogenesis of SARS-CoV-2 infection through clinical studies and observations of elevated complement levels.5 This article broadly overviews the current state of knowledge on the neurological manifestations of SARS-CoV-2 infection. We discuss the current understanding of the pathogenesis of complement overactivation in COVID-19 and describe how each consequence may be related to these neurological manifestations. We also review current therapeutic avenues in this regard.

Neurological manifestations of SARS-CoV-2 infection

The neurological symptoms of SARS-CoV-2 infection can be broadly divided into central nervous system (CNS) and peripheral nervous system (PNS) complications. CNS complications include encephalopathy and encephalitis, cerebrovascular disease and headaches, and other, rarer, complications.3,6–8 PNS complications include neuromuscular disease, autonomic dysfunction, and altered taste and smell sensations. Psychiatric symptoms such as depression, psychotic symptoms, anxiety, hallucinations and altered mood are also associated with SARS-CoV-2 infection;6 however, for the purpose of this review, discussion of these is deferred.

Central nervous system involvement in SARS-CoV-2 infection

Non-vascular central nervous system complications

Symptoms of encephalopathy and encephalitis due to SARS-CoV-2 infection include confusion, lethargy, delirium, somnolence and coma. These symptoms in patients with SARS-CoV-2 infection usually occur due to systemic illness resulting in a metabolic encephalopathy, most commonly from hypoxia or renal dysfunction.9 The risk factors are in line with established risk factors for encephalopathy, which include old age, dementia and a history of cerebrovascular disease.9 The overall pooled prevalence of these symptoms of encephalopathy and encephalitis in patients with COVID-19 as a whole has been estimated to be between 7–11%.8,10 The severity of SARS-CoV-2 infection has also been associated with an increased risk of developing these symptoms. Patients who are critically ill with COVID-19 have a much higher incidence of delirium and coma, with sedation due to mechanical ventilation playing a significant role.7,10 Headaches are associated with SARS-CoV-2 infection and are postulated to be related to fevers, systemic inflammatory mediator release or direct viral invasion of nerve endings.11 Headaches occur in 11–14% of patients with SARS-CoV-2 infection and are gradual in onset, moderate or severe, and bilateral headaches around the forehead, temporoparietal and periorbital regions.12

Additionally, acute necrotizing encephalopathy, leukoencephalopathy and demyelinating lesions in the brain and spine, with multiple focal lesions and necrosis in various locations, which are likely to be related to cytokine storm, have been reported after SARS-CoV-2 infection.13 

Vascular central nervous system complications

Cerebrovascular disease due to SARS-CoV-2 infection comprises primarily ischaemic and haemorrhagic strokes and cerebral venous thrombosis.14 The cause of ischaemic stroke is currently unclear and likely multifactorial, but hypotheses include a prothrombotic and hypercoagulable state due to inflammatory cytokine storm, viral invasion resulting in endothelial dysfunction and vasoconstriction, and hypoxaemia leading to the activation of hypoxia genes and thrombotic events.15 Haemorrhagic stroke, which is less common, is hypothesized to be related to angiotensin-converting enzyme-2 (ACE2) receptors in blood vessel walls, which allow the virus to damage and rupture vessels, along with the downregulation of the renin-angiotensin system, which increases blood pressure; the viral infection may also be related to the consumption of coagulation factors.14 Cerebral venous thrombosis is associated with SARS-CoV-2 infection through the classic mechanism of hypercoagulable state, along with endothelial damage and stasis leading to the generation of thrombi.16 These haemostatic abnormalities are demonstrated by increased fibrin degradation products and D-dimers, as well as intravascular coagulopathy.17 In patients with SARS-CoV-2 infection, the pooled prevalence is 1.00% for ischaemic stroke, 0.31% for haemorrhagic stroke and 0.12% for venous thrombosis.10 Ischaemic stroke has been linked to hypercoagulability, vasculitis and cardiac dysfunction.18 Haemorrhagic complications are possibly due to endothelial rupture from viral neuroinvasion, secondary haemorrhagic transformation of ischaemic strokes or massive cytokine release and breakdown of the blood–brain barrier.18

Peripheral nervous system involvement in SARS-CoV-2 infection

Muscular complications

Muscle damage such as rhabdomyolysis and myalgias, which can be caused by generalized inflammation, may be associated with SARS-CoV-2 infection through a form of immune response known as cytokine storm.6 The pooled prevalence of muscle damage among all patients with COVID-19 is reported to be 20.00% for myalgia, 5.00% for skeletal muscle injury and 0.39% for rhabdomyolysis.6,10 Direct viral invasion of the muscle has also been hypothesized, leading to myositis and breakdown.19 Patients who are critically ill with COVID-19 and require mechanical ventilation with specific neuromuscular blocking agents have been observed with myopathy; however, this is not specific to COVID-19.6

Nerve-related complications

PNS nerve complications associated with SARS-CoV-2 infection include inflammatory neuropathies such as Guillain–Barré syndrome (GBS) and Miller Fisher syndrome (MFS), autonomic neuropathy, small fibre neuropathies and other neuropathies causing neuropathic pain, and cranial neuropathies causing anosmia and ageusia.6 Molecular mimicry between viral proteins and peripheral nerve proteins resulting in damage to neuronal myelin and axons has been found to be the established mechanism of GBS and MFS after any viral illness, including SARS-CoV-2 infection.6 GBS after SARS-CoV-2 infection has been described with lower-limb weakness and, eventually, generalized weakness and paralysis of all four limbs, and MFS is recognized as the variant with ophthalmoplegia, areflexia and ataxia.2 The pooled prevalence among all patients with COVID-19 is 0.28% for GBS and 0.05% for MFS.10

Anosmia and ageusia are well-known symptoms of SARS-CoV-2 infection.20 The mechanism for these effects is hypothesized to be a direct viral invasion of the olfactory epithelium due to ACE2 neurotropism.21 In patients with COVID-19, impairment of smell has a pooled prevalence of 19%, and loss of taste has a pooled prevalence of 21%,10 with an earlier study estimating the combined loss of taste and smell to have a pooled prevalence of 35%.22 Anosmia has been associated with milder cases and is a prognostic factor for lower mortality due to SARS-CoV-2 infection.23

Autonomic dysfunction includes changes in blood pressure, heart rate, respiratory rate and temperature and can manifest with symptoms including fatigue, bladder dysfunction and gastrointestinal symptoms such as nausea.24 These symptoms are reported during both the acute phase of SARS-CoV-2 infection and in the weeks to months after the viral illness has passed.25 The mechanism of these symptoms is postulated to be related to viral invasion and inflammation of the median eminence of the hypothalamus and the brainstem resulting in the release of hormonal mediators. It could also be related to autoantibodies against certain receptors.25

Rarer neurological manifestations of SARS-CoV-2 infection

Rarer neurological complications of SARS-CoV-2 infection have been reported, including encephalitis and meningitis.7 The description of these cases varies, ranging from typical to atypical; there are also disparate reports about the detection of SARS-CoV-2 in the cerebrospinal fluid of patients with these diseases.7 An autoimmune cause of encephalitis as a post-infectious syndrome has been suggested.26 Seizures have been reported as well, but these could be related to febrile illness, as they are very infrequently reported in COVID-19 cohorts. For example, in a study of 6,147 patients with COVID-19, the rate of seizures was only 0.08%.27

Pathogenesis of neurological manifestations of SARS-CoV-2 infection: excessive complement activation

The complement system is an essential and critical component of the innate and adaptive immune response in humans that works via opsonization, inflammatory mediation and cytolysis. This system comprises a series of proteolytic reactions that is activated through three pathways: classical, lectin and alternative.4 These different pathways funnel into a common pathway, resulting in the formation of C3 convertase, which cleaves the C3 protein leaving the C3a and C3b components.4 C3a is a proinflammatory molecule, and C3b plays a role in opsonizing pathogens and forming C5 convertase, which releases C5a, a proinflammatory molecule, and C5b, which forms part of the membrane attack complex (C5b-C9) (Figure 1).4

Although this system is beneficial and essential in combatting bacterial and viral infections, excessive activation, for example, during SARS-CoV-2 infection, can result in direct host damage. The activation of complement as part of the coronavirus disease process was described in a 2018 study on the earlier SARS-CoV-1, where mice that were C3 deficient demonstrated a milder form of the disease, with lower levels of inflammatory cytokines compared with wild-type mice, even in the presence of equivalent viral loads.28

Evidence for this in clinical studies of SARS-CoV-2 infections implicates complement in the development of COVID-19, as well as in the disease severity. In an ultra-high throughput clinical proteomics study of sera of patients with severe SARS-CoV-2 infection, consistent activation of components of the classical and alternative pathways was observed.29 In a study on five individuals with severe SARS-CoV-2 infection, complement components such as C5b-C9, C4d and mannose-binding lectin-associated serine protease (MASP)-2 were deposited in pulmonary and cutaneous tissue, suggesting that widespread complement activation through the alternative and lectin pathways may cause generalized thrombotic microvascular injury.30 In a prospective single-centre study of 197 patients, C3a, C3c and C5b-C9 were elevated in the plasma of patients with COVID-19 compared with healthy controls, with significantly higher C3a and C5b-C9 concentration in COVID-19 cases in the intensive care unit compared with non-intensive care unit cases and higher mortality in patients with consistently elevated C3a.31 Similarly, C3 hyperactivation was an independent risk factor of mortality in a prospective cohort study of 102 inpatients with COVID-19.32 In a prospective cohort study of 39 patients with SARS-CoV-2 infection, C5b-C9 and C4d at admission were significantly elevated in patients with respiratory failure compared with patients without respiratory failure.33 These elevated levels were found days to weeks after admission, demonstrating persistent activation. In a study of 72 patients with COVID-19, a genetic variant at a specific multigene cluster was associated with increased SARS-CoV-2 infection severity and increased activation of complement, with high circulating C5a and C5b-C9.34 Elevated C5a was used in a prognostic model for SARS-CoV-2 infection that predicted severity and mortality significantly.35

Overall, C5a, C3a and C5b-C9 clearly increase in SARS-CoV-2 infection and with disease severity in the literature.36 Even compared with other viruses, such as influenza leading to acute respiratory failure, complement activation is higher and distinguishes patients with worse outcomes.5 However, it has been hypothesized that this aberrant dysregulation of complement may simply lead to greater susceptibility to severe disease.36 Nevertheless, excess activation of complement is clearly involved in severe COVID-19, with the precise mechanism still under investigation.

Mechanism of activation of complement in SARS-CoV-2 infection

The mechanism of complement activation through the lectin pathway in SARS-CoV-2 is related to lectin pathway recognition molecules ficolin-2, collectin-11 and MASP-2 binding to the S and N proteins of SARS-CoV-2.37,38 Subsequently, through the lectin pathway, the deposition of C3b and C4a occurs.37 Further, the SARS-CoV-2 S protein, but not the N protein, activates the alternative pathway by interacting with the cell surface and binding to heparan sulphate, allowing for the generation of C3 convertase.39 Moreover, the SARS-CoV-2-induced expression of C3 through a Janus kinase signal/transducer and activator of transcription pathway leads to activating C3a through the alternative pathway component complement factor B.40 Specifically, components of the alternative pathway are associated with worse outcomes for patients with SARS-CoV-2 infection and are associated with markers of endothelial damage and hypercoagulability.5 The classical pathway may also be activated through a direct viral invasion of endothelial cells, through ACE2 receptors by SARS-CoV-2, and through the exposure of damage-associated molecular patterns.41 Immunoglobulin G against SARS-CoV-2 activates the classical pathway, resulting in excess inflammation.42 Mannose-binding lectin has been suggested to play a role in thrombosis in SARS-CoV-2 infection; once bound to the target, it circulates with MASPs, which activate complement and are also involved in clotting.43 C5a, with its receptor C5aR and C3a, have been postulated in SARS-CoV-2 infection to increase the recruitment of myeloid cells,44 which then secrete inflammatory molecules such as interleukin 6, tumour necrosis factor a, and interleukin 1b, leading to a cytokine storm.45 In general, this activation may further lead to endothelial damage, inflammation and thrombosis, all of which may be implicated in the various neurological manifestations of SARS-CoV-2 infection (Figure 2).37,40,41,46 We review each consequence of complement overactivation in the context of the neurological manifestations of SARS-CoV-2 infection.

Endothelial damage in the central nervous system

Complement overactivation results in endothelial injury and reveals the basement membrane, which can lead to the activation of clotting factors.46 In a study using a mouse model, complement activation was found to contribute to endothelial dysfunction, and SARS-CoV-2 infection was found to upregulate the kirsten rat sarcoma pathway.47 This pathway increases the expression of serpin genes, which were similarly upregulated in the blood–brain barrier of mouse multiple sclerosis models, indicating a loss of the endothelial barrier function and vascular permeability.47 Disruption of the vasculature in the brain through an unknown mechanism has been described in postmortem studies of the brains of patients with COVID-19.48 A current theory for ischaemic and haemorrhagic strokes in SARS-CoV-2 infection is the direct viral invasion through disruption of the blood–brain barrier.49,50 A hypothesized pathway involves the zonulin protein, a regulatory protein of tight junctions in various tissues that is known to induce complement, the overactivation of which has been linked to increased permeability and, possibly, to SARS-CoV-2 neuroinvasion.51 Neuroinvasion is thought to result in cerebral sinus venous thrombosis, as well as the meningitis and encephalitis seen in SARS-CoV-2 infection.52 Additionally, complement-mediated endothelial damage through C5b-C9 has been linked to the release of extracellular vesicles, which increase the prothrombotic environment.53 These vesicles could serve as markers of endothelial injury and ischaemic stroke in SARS-CoV-2 infection.53 In a recent autopsy study of the brains of nine patients with COVID-19 by Lee et al., disruption of the blood–brain barrier, implied by the presence of large proteins, which do not usually cross the barrier, was found in all patients.54 This endothelial dysfunction was suggested to be complement mediated, as the deposition of complement components was observed. Lee et al. proposed that SARS-CoV-2 infection triggers immune complexes through the classical pathway, which cause multiple areas of endothelial activation leading to platelet activation, thrombi and, eventually, inflammation; this results in microglia activation, which causes neuronal injury.54 A disordered activation of complement, which can occur due to SARS-CoV-2, can trigger neuroinflammation through nuclear factor k-light-chain-enhancer of activated B cells, microRNA and caspases, leading to apoptosis in the brain.55

Hyperinflammation in the central and peripheral nervous systems and muscle

The elevated levels of proinflammatory cytokines in patients with COVID-19 and, specifically, more severe types may be promoted by C3a and C5a, as previously mentioned. However, this is likely only a component of the process, as a whole host of cytokines work together in a cascade, leading to massive multiorgan inflammation.45 This cytokine storm is associated with the autonomic dysfunction that has been observed in SARS-CoV-2 infection through increased sympathetic activation and parasympathetic withdrawal.56 Additionally, complement activates neutrophil extracellular traps (NETs), which can lead to autoimmunity, manifestations of which include GBS, myositis and myalgia,57 although this link has yet to be investigated. C3a, C5a and C5b-C9 are all elevated in the cerebrospinal fluid of patients with GBS and have a role in axon damage and demyelination.58 Pathological specimens of nerves from patients with GBS have deposits of C3 and C5b-C9, which have been suggested to be involved in the damage.59 This deposition leads to myelin damage and infiltration with inflammatory cells.59 Moreover, anosmia and ageusia associated with COVID-19 are thought to be due to the viral invasion of the neuro-epithelium.60 Similarly, smell dysfunctions have been reported in autoimmune diseases characterized by the overactivation of the complement system, suggesting that this excess complement activation could play a role in anosmia.60 Despite the suggestion that pulmonary infection is the main cause of death due to COVID-19, cytokine storm has been suggested as a mechanism of pathological changes in the brain.47 Interestingly, complement has been hypothesized to be related to the delirium observed in patients who are critically ill with COVID-19 through hyperinflammation.61

Complement has been clearly described in the mechanism of inflammatory myopathies and has been suggested to be involved in SARS-CoV-2 infection as a trigger of these myopathies.62 C5b-C9 is deposited on endothelial cells in patients with dermatomyositis even before muscle destruction has occurred; the activation of complement recruits inflammatory cells leading to endothelial cell necrosis and microinfarcts.59 A similar mechanism may be present in patients with COVID-19, leading to the wide spectrum of muscle damage observed.

Hypercoagulability and thrombosis in the central nervous system

Currently, a ‘two-hit’ hypothesis has been proposed to describe the link between complement and thrombosis in COVID-19, wherein the first relates to mutations or acquired changes in complement regulatory proteins or C3 convertase, and the second is an inflammatory trigger.63 This link in SARS-CoV-2 infection is commonly compared to thrombotic thrombocytopenic purpura, where a genetic disposition and subsequent inciting factor lead to thrombosis.64 Although it is still unknown why some patients develop mild versus severe SARS-CoV-2 infection, a possible explanation could be variations in complement genes leading to stronger complement activation, excess complement deposition and progressive thrombotic microangiopathy (TMA), and, thus, worse outcomes.65 TMA leads to decreased blood flow, resulting in ischaemia, injury and eventual organ failure. Indeed, single-nucleotide polymorphisms of complement regulators, which allow for overactivation, are associated with adverse outcomes in SARS-CoV-2 infection.66 Diffuse microvascular thromboses have been found in the autopsy of patients with SARS-CoV-2 infection and are similar to those found in SARS-CoV-1 infection, including those found in the brain.67

Complement shows considerable interaction with coagulation pathways, and both are closely linked with significant crosstalk, such that it has been suggested that both pathways are evolutionary descendants of a common immune proteolytic system.68,69 The interactions between complement and the clotting and coagulation pathways include thrombin activating C5 independently of C3 and high levels of von Willebrand factor (vWF), factor XII, kallikrein, and platelets, which trigger complement activation and the subsequent release of C5a, C5b-C9 and MASPs, which facilitate thrombosis.64 These pathways lead to an escalating cycle of damage to surrounding tissue and may play a role in the development of large-vessel stroke seen in SARS-CoV-2 infection.64 Furthermore, NETs activated by complement are also implicated in thrombosis in SARS-CoV-2 infection through tissue factor,70 fibrinogen, vWF and fibronectin.71 NETs are associated with more severe SARS-CoV-2 infection and play a role in the occlusion of arteries and venous thrombosis,72,73 and, thus, possibly stroke.68,74 In a case report of a patient with COVID-19 and complement-mediated thrombosis, it was hypothesized that the transient elevation of anti-phospholipid antibodies triggered by SARS-CoV-2 may have contributed to coagulopathy.75 As complement activation is necessary for anti-phospholipid-mediated thrombosis,75 this could serve as another mechanism of stroke. The kallikrein-kinin system (KKS) is another part of the immune system and has extensive crosstalk with complement in a manner that has led to hypothesizing that KKS is overactivated in SARS-CoV-2 infection, exacerbating hypercoagulation.76 KKS is an important driver of thrombus formation in stroke.77 Clinically, coagulopathy in patients with COVID-19 is usually characterized by elevated D-dimer, fibrinogen, vWF and factor VIII, and only mildly elevated or normal platelet count, activated partial thromboplastin time and prothrombin time, suggesting a pattern similar to that established in complement-associated TMA.64,78

Excess complement after coronavirus disease 2019 vaccination leading to neurological complications

COVID-19 vaccination is associated with the development of stroke, specifically ischaemic stroke and cerebral venous thrombosis, although the overall reporting rate of stroke did not increase during the vaccine rollout.79,80 It has been hypothesized that the immune response to the vaccine can overactivate complement, leading to endothelial disruption and hypercoagulability and creating the necessary environment for stroke.81 Additionally, in a case of COVID-19 vaccine-induced thrombotic thrombocytopenia, compared with controls, complement components were detectable in the vaccine-induced thrombotic thrombocytopenia thrombi, implicating complement in the pathogenesis.82 The hypothesized mechanism through which the COVID-19 vaccine overactivates complement is related to anti-platelet factor 4 autoantibodies, which could facilitate the activation of C3. Additionally, the binding of complement to the anti-platelet factor 4 immune complexes can lead to complement activation through the classical pathway.83 A variety of neurological adverse events are associated with COVID-19 vaccination; these events include stroke, encephalopathy, GBS and rhabdomyolysis.84 Complement may play a role, though further investigation is needed.

Excess complement in neurological post-acute sequelae of coronavirus disease 2019

Long-haul COVID-19, also known as long COVID and post-acute sequelae of COVID-19, is a collection of heterogeneous symptoms and complications that follow the acute infectious phase, usually 4 weeks, and that last for more than 6 months.85 Complement elevation with sustained inflammation has been observed in patients with long-haul COVID-19. Long-term respiratory symptoms, for example, are associated with high C5a levels, suggesting a mechanistic function as well as a potential biomarker.86 Additionally, elevated C3 has been seen in patients with persistent lung abnormalities after COVID-19.87 Neurological symptoms of long-haul COVID-19 include CNS symptoms such as ‘brain fog’, difficulty concentrating, memory problems, anxiety, and insomnia and PNS symptoms such as autonomic dysfunctions, neuropathic pain, muscle damage, and peripheral neuropathies.88 Complement overactivation and deposition in the brain, which lead to inflammation, damage and neuron death, have been postulated by Lee et al. to be involved in the progression of long-haul COVID-19.54 In their study, the authors found pathological findings from SARS-CoV-2 infection, particularly in the hindbrain, that could have come from the viral invasion of the brainstem through the vagus nerve.54 The vagus nerve is involved in both respiratory and gastrointestinal function, and viral invasion and subsequent hyperinflammation could explain the persistent autonomic dysfunction observed in long-haul COVID-19.54,56

Complement inhibition: a potential therapeutic option for SARS-CoV-2 infection

The current landscape of complement inhibition as an intervention for SARS-CoV-2 infection primarily uses existing drugs for complement-mediated diseases. These diseases include complementopathies such as macular degeneration, atypical haemolytic uraemic syndrome, paroxysmal nocturnal haemoglobinuria, complement nephropathies and myasthenia gravis.89 Inhibitors of C5a, such as eculizumab, have shown varying but positive results. Eculizumab treatment improved survival in 35 patients,90 decreased mortality and discharge with complications in 10 patients,91 decreased inflammatory markers in four patients,92 improved clinical status in eight pregnant patients and improved symptoms in 13 patients.93,94 However, in a clinical trial of 135 patients, another C5 inhibitor, ravulizumab, did not show clinical benefit, and the trial was terminated.89 C5 inhibition has and is being studied with eculizumab (Eculizumab [Soliris] in COVID-19 infected patients [SOLID-C19]; identifier: NCT04288713; CORIMUNO19-ECU: Trial evaluating efficacy and safety of eculizumab [Soliris] in patients with COVID-19 infection, nested in the CORIMUNO-19 cohort; identifier: NCT04346797), tesidolumab95 and peptide antagonists such as nomacopan96 and zilucoplan (Zilucoplan® in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure [ZILU-COV]; identifier: NCT04382755).89

C3 inhibition using AMY-101 has been reported in four patients with SARS-CoV-2 infection, all of whom recovered.97,98 However, a phase I/II clinical trial (A study of APL-9 in adults with mild to moderate ARDS due to COVID-19; identifier: NCT04402060) in 65 patients treated with the C3 inhibitor APL-9 found no difference in mortality.89 In six patients, inhibition of MASP-2, which is involved in the lectin pathway, using narsoplimab resulted in the survival of all patients with severe SARS-CoV-2 infection.99 Conestat alfa, a C1 inhibitor from the classical pathway, was used in five patients and resulted in clinical improvement and recovery in four patients.100 However, these positive results must be weighed against an increased risk of severe bacterial infections. Several patients on eculizumab developed bacterial infections, in some cases resulting in death.36 These infections occurred even in the presence of antibiotic prophylaxis and vaccination.89


The aberrant dysregulation of the complement system resulting in excess activation clearly plays a role in at least a subset of patients with SARS-CoV-2 infection. Genetic susceptibilities of variants and regulators of complement genes, as well as specific risk factors, may determine which patients develop a severe infection. Through complement, the interconnected triad of endothelial damage, thrombosis and hyperinflammation is undoubtedly involved in the development of certain neurological manifestations of SARS-CoV-2 infection, especially cerebrovascular disease. The increased inflammation and cytokine storm associated with complement likely plays a role in manifestations such as muscle and nerve injury, although studies have yet to explore this link in depth in the context of SARS-CoV-2 infection. Neurological manifestations result in enormous morbidity for patients with COVID-19, and there are still limited data on their long-term effects; therapies targeting complement may mitigate these effects. Currently, however, complement inhibition requires more randomized clinical trials before being recommended to all patients with COVID-19, if at all. It is likely that once more is elucidated on the mechanism and involved pathways, complement inhibition may be the choice for selected patients with COVID-19.

Article Information:

Mustafa Jaffry, Iqra Faiz, Kazim Jaffry and Nizar Souayah have no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.


The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.


Nizar Souayah, Department of Neurology, New Jersey Medical School, 90 Bergen Street DOC 8100, Newark, NJ 07101, USA. E:


No funding was received in the publication of this article.


This article is freely accessible at © Touch Medical Media 2022


All figures were made in ©BioRender.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.




  1. Hu J, Wang Y. The clinical characteristics and risk factors of severe COVID-19. Gerontology. 2021;67:255–66.
  2. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021;268:3059–71.
  3. Galea M, Agius M, Vassallo N. Neurological manifestations and pathogenic mechanisms of COVID-19. Neurol Res.2022;44:571–82.
  4. Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33:479–92.
  5. Ma L, Sahu SK, Cano M, et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol.2021;6:eabh2259.
  6. Roy D, Ghosh R, Dubey S, et al. Neurological and neuropsychiatric impacts of COVID-19 pandemic. Can J Neurol Sci.2021;48:9–24.
  7. Hensley MK, Markantone D, Prescott HC. Neurologic manifestations and complications of COVID-19. Annu Rev Med. 2022;73:113–27.
  8. Favas TT, Dev P, Chaurasia RN, et al. Neurological manifestations of COVID-19: A systematic review and meta-analysis of proportions. Neurol Sci.2020;41:3437–70.
  9. Antoniello D, Milstein MJ, Dardick J, et al. Altered mental status in COVID-19. J Neurol. 2022;269:12–8.
  10. Misra S, Kolappa K, Prasad M, et al. Frequency of neurologic manifestations in COVID-19: A systematic review and meta-analysis. Neurology. 2021;97:e2269–e81.
  11. Bobker SM, Robbins MS. COVID-19 and headache: A primer for trainees. Headache. 2020;60:1806–11.
  12. Bolay H, Gul A, Baykan B. COVID-19 is a real headache! Headache. 2020;60:1415–21.
  13. Thepmankorn P, Bach J, Lasfar A, et al. Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations. Cytokine. 2021;138:155404.
  14. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: A systematic review and meta-analysis. Int J Stroke.2021;16:137–49.
  15. Luo W, Liu X, Bao K, Huang C. Ischemic stroke associated with COVID-19: A systematic review and meta-analysis.J Neurol. 2022;269:1731–40.
  16. Ghosh R, Roy D, Mandal A, et al. Cerebral venous thrombosis in COVID-19. Diabetes Metab Syndr. 2021;15:1039–45.
  17. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2950–73.
  18. Spence JD, de Freitas GR, Pettigrew LC, et al. Mechanisms of stroke in COVID-19. Cerebrovasc Dis.2020;49:451–8.
  19. Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and myositis: What we know so far. Curr Rheumatol Rep. 2021;23:63.
  20. Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: A review based on up-to-date knowledge. Am J Otolaryngol.2020;41:102581.
  21. Khatoon F, Prasad K, Kumar V. COVID-19 associated nervous system manifestations. Sleep Med. 2022;91:231–6.
  22. Ibekwe TS, Fasunla AJ, Orimadegun AE. Systematic review and meta-analysis of smell and taste disorders in COVID-19. OTO Open. 2020;4:2473974X20957975.
  23. Sampaio Rocha-Filho PA, Magalhaes JE, Fernandes Silva D, et al. Neurological manifestations as prognostic factors in COVID-19: A retrospective cohort study. Acta Neurol Belg. 2022;122:725–33.
  24. Becker RC. Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series. J Thromb Thrombolysis.2021;52:692–707.
  25. Erdal Y, Atalar AC, Gunes T, et al. Autonomic dysfunction in patients with COVID19.Acta Neurol Belg. 2022;122:885–91.
  26. Nabizadeh F, Balabandian M, Sodeifian F, et al. Autoimmune encephalitis associated with COVID-19: A systematic review. Mult Scler Relat Disord. 2022;62:103795.
  27. Emami A, Fadakar N, Akbari A, et al. Seizure in patients with COVID-19. Neurol Sci.2020;41:3057–61.
  28. Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9:e01753–18.
  29. Messner CB, Demichev V, Wendisch D, et al. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection.
    Cell Syst. 2020;11:11–24.e4.
  30. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res.2020;220:1–13.
  31. de Nooijer AH, Grondman I, Janssen NAF, et al. Complement activation in the disease course of coronavirus disease 2019 and its effects on clinical outcomes. J Infect Dis. 2021;223:214–24.
  32. Sinkovits G, Mezo B, Reti M, et al. Complement overactivation and consumption predicts in-hospital mortality in SARS-CoV-2 infection. Front Immunol.2021;12:663187.
  33. Holter JC, Pischke SE, de Boer E, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A. 2020;117:25018–25.
  34. Valenti L, Griffini S, Lamorte G, et al. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19.J Autoimmun. 2021;117:102595.
  35. Cyprian FS, Suleman M, Abdelhafez I, et al. Complement C5a and clinical markers as predictors of COVID-19 disease severity and mortality in a multi-ethnic population. Front Immunol. 2021;12:707159.
  36. Kurtovic L, Beeson JG. Complement factors in COVID-19 therapeutics and vaccines. Trends Immunol.2021;42:94–103.
  37. Ali YM, Ferrari M, Lynch NJ, et al. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front Immunol.2021;12:714511.
  38. Götz MP, Skjoedt MO, Bayarri-Olmos R, et al. Lectin pathway enzyme MASP-2 and downstream complement activation in COVID-19.J Innate Immun. 2022:1–14. doi: 10.1159/000525508.
  39. Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020;136:2080–9.
  40. Yan B, Freiwald T, Chauss D, et al. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Sci Immunol. 2021;6:eabg0833.
  41. Conway EM, Pryzdial ELG. Is the COVID-19 thrombotic catastrophe complement-connected? J Thromb Haemost. 2020;18:2812–22.
  42. Jarlhelt I, Nielsen SK, Jahn CXH, et al. SARS-CoV-2 antibodies mediate complement and cellular driven inflammation. Front Immunol. 2021;12:767981.
  43. Eriksson O, Hultstrom M, Persson B, et al. Mannose-binding lectin is associated with thrombosis and coagulopathy in critically ill COVID-19 patients. Thromb Haemost.2020;120:1720–4.
  44. Carvelli J, Demaria O, Vely F, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020;588:146–50.
  45. Chouaki Benmansour N, Carvelli J, Vivier E. Complement cascade in severe forms of COVID-19: Recent advances in therapy. Eur J Immunol. 2021;51:1652–9.
  46. Perico L, Benigni A, Casiraghi F, et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17:46–64.
  47. Qin Z, Liu F, Blair R, et al. Endothelial cell infection and dysfunction, immune activation in severe COVID-19. Theranostics. 2021;11:8076–91.
  48. Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med.2021;218:e20202135.
  49. Hernandez-Fernandez F, Sandoval Valencia H, Barbella-Aponte RA, et al. Cerebrovascular disease in patients with COVID-19: Neuroimaging, histological and clinical description. Brain. 2020;143:3089–103.
  50. Barbosa LC, Goncalves TL, de Araujo LP, et al. Endothelial cells and SARS-CoV-2: An intimate relationship. Vascul Pharmacol. 2021;137:106829.
  51. Llorens S, Nava E, Munoz-Lopez M, et al. Neurological symptoms of COVID-19: The zonulin hypothesis. Front Immunol. 2021;12:665300.
  52. Gavriilaki E, Anyfanti P, Gavriilaki M, et al. Endothelial dysfunction in COVID-19: Lessons learned from coronaviruses. Curr Hypertens Rep. 2020;22:63.
  53. Inal J. Complement-mediated extracellular vesicle release as a measure of endothelial dysfunction and prognostic marker for COVID-19 in peripheral blood – Letter to the Editor. Clin Hemorheol Microcirc.2020;75:383–6.
  54. Lee MH, Perl DP, Steiner J, et al. Neurovascular injury with complement activation and inflammation in COVID-19. Brain. 2022;145:2555–68.
  55. Welcome MO, Mastorakis NE. Neuropathophysiology of coronavirus disease 2019: Neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection. Inflammopharmacology. 2021;29:939–63.
  56. Hassani M, Fathi Jouzdani A, Motarjem S, et al. How COVID-19 can cause autonomic dysfunctions and postural orthostatic syndrome? A review of mechanisms and evidence. NeurolClin Neurosci. 2021;9:434–42.
  57. Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol. 2021;40:2611–9.
  58. Meidaninikjeh S, Sabouni N, Taheri M, et al. SARS-CoV-2 and Guillain–Barré syndrome: Lessons from viral infections. Viral Immunol. 2022;35:404–17.
  59. Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16:601–17.
  60. Conigliaro P, Triggianese P, Perricone C, et al. COVID-19: Discovering the role of complement system. Clin Exp Rheumatol. 2020;38:587–91.
  61. de Miranda Santos IKF, de Barros Cardoso CR. Commentary on “Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. Clin Immunol. 2021;222:108618.
  62. Dalakas MC. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Rev Clin Immunol. 2022;18:413–23.
  63. Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: Success does not come easily. Br J Haematol. 2020;189:e227–30.
  64. Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: Friend and foe? JCI Insight. 2020;5:e140711.
  65. Jodele S, Kohl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol.2021;178:2832–48.
  66. Ramlall V, Thangaraj PM, Meydan C, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020;26:1609–15.
  67. Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis? 2020;141:1739–41.
  68. Tomo S, Kumar KP, Roy D, et al. Complement activation and coagulopathy – An ominous duo in COVID19. Expert Rev Hematol.2021;14:155–73.
  69. Iwanaga S, Lee BL. Recent advances in the innate immunity of invertebrate animals. J Biochem Mol Biol. 2005;38:128–50.
  70. Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020;130:6151–7.
  71. Chauhan AJ, Wiffen LJ, Brown TP. COVID-19: A collision of complement, coagulation and inflammatory pathways. J Thromb Haemost. 2020;18:2110–7.
  72. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5:e138999.
  73. Zuo Y, Kanthi Y, Knight JS, Kim AHJ. The interplay between neutrophils, complement, and microthrombi in COVID-19. Best Pract Res Clin Rheumatol.2021;35:101661.
  74. Satyam A, Tsokos GC. Curb complement to cure COVID-19. Clin Immunol. 2020;221:108603.
  75. Showers CR, Nuovo GJ, Lakhanpal A, et al. A Covid-19 patient with complement-mediated coagulopathy and severe thrombosis. Pathobiology. 2021;88:28–36.
  76. Hoevenaar M, Goossens D, Roorda J. Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads.J Renin Angiotensin Aldosterone Syst. 2020;21:1470320320979097.
  77. Gob E, Reymann S, Langhauser F, et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Ann Neurol. 2015;77:784–803.
  78. Colling ME, Kanthi Y. COVID-19-associated coagulopathy: An exploration of mechanisms. Vasc Med. 2020;25:471–8.
  79. Yoshida K, Tanaka K, Suto Y, Fukuda H. Repeated cardioembolic stroke after COVID-19 mRNA vaccination: A case report.J Stroke Cerebrovasc Dis. 2022;31:106233.
  80. Schulz JB, Berlit P, Diener HC, et al. COVID-19 vaccine-associated cerebral venous thrombosis in Germany. Ann Neurol. 2021;90:627–39.
  81. Famularo G. Stroke after COVID-19 vaccination. Acta Neurol Scand. 2022;145:787–8.
  82. de Buhr N, Baumann T, Werlein C, et al. Insights into immunothrombotic mechanisms in acute stroke due to vaccine-induced immune thrombotic thrombocytopenia. Front Immunol. 2022;13:879157.
  83. Mastellos DC, Skendros P, Lambris JD. Is complement the culprit behind COVID-19 vaccine-related adverse reactions? J Clin Invest. 2021;131:e151092.
  84. Sriwastava S, Sharma K, Khalid SH, et al. COVID-19 vaccination and neurological manifestations: A review of case reports and case series. Brain Sci.2022;12:407.
  85. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–15.
  86. Senent Y, Inoges S, Lopez-Diaz de Cerio A, et al. Persistence of high levels of serum complement C5a in severe COVID-19 cases after hospital discharge. Front Immunol. 2021;12:767376.
  87. Chi H, Zhou K, Shen L, et al. The evaluation of the immune status of COVID-19 recovered subjects with persistent abnormal lung CT after one year: A longitudinal cohort study. Int Immunopharmacol. 2022;110:109019.
  88. Walitt B, Johnson TP. The pathogenesis of neurologic symptoms of the postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Neurol.2022;35:384–91.
  89. Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol.2022;22:77–84.
  90. Annane D, Heming N, Grimaldi-Bensouda L, et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine. 2020;28:100590.
  91. Ruggenenti P, Di Marco F, Cortinovis M, et al. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One. 2021;16:e0261113.
  92. Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci.2020;24:4040–7.
  93. Laurence J, Mulvey JJ, Seshadri M, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555.
  94. Giudice V, Pagliano P, Vatrella A, et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: A controlled study.Front Pharmacol. 2020;11:857.
  95. Zelek WM, Cole J, Ponsford MJ, et al. Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19. Am J Respir Crit Care Med.2020;202:1304–8.
  96. Higenbottam TW, Berstein J, Meollman J, et al. Compassionate use of an anti-C5 inhibitor, nomacopan, positively influenced the course and progression of disease in Covid-19. Am J Respir Crit Care Med. 2022;205:A5761.
  97. Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020;215:108450.
  98. Mastellos DC, Pires da Silva BGP, Fonseca BAL, et al. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol. 2020;220:108598.
  99. Rambaldi A, Gritti G, Mico MC, et al. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020;225:152001.
  100. Urwyler P, Moser S, Charitos P, et al. Treatment of COVID-19 with conestat alfa, a regulator of the complement, contact activation and kallikrein-kinin system.Front Immunol. 2020;11:2072.

Further Resources

Share this Article
Related Content In COVID-19
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72